143 related articles for article (PubMed ID: 20655210)
1. X-ray crystal structure of JNK2 complexed with the p38alpha inhibitor BIRB796: insights into the rational design of DFG-out binding MAP kinase inhibitors.
Kuglstatter A; Ghate M; Tsing S; Villaseñor AG; Shaw D; Barnett JW; Browner MF
Bioorg Med Chem Lett; 2010 Sep; 20(17):5217-20. PubMed ID: 20655210
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling.
Gruenbaum LM; Schwartz R; Woska JR; DeLeon RP; Peet GW; Warren TC; Capolino A; Mara L; Morelock MM; Shrutkowski A; Jones JW; Pargellis CA
Biochem Pharmacol; 2009 Feb; 77(3):422-32. PubMed ID: 19027720
[TBL] [Abstract][Full Text] [Related]
3. Displacement assay for the detection of stabilizers of inactive kinase conformations.
Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
[TBL] [Abstract][Full Text] [Related]
4. The crystal structure of JNK2 reveals conformational flexibility in the MAP kinase insert and indicates its involvement in the regulation of catalytic activity.
Shaw D; Wang SM; Villaseñor AG; Tsing S; Walter D; Browner MF; Barnett J; Kuglstatter A
J Mol Biol; 2008 Nov; 383(4):885-93. PubMed ID: 18801372
[TBL] [Abstract][Full Text] [Related]
5. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo.
Kuma Y; Sabio G; Bain J; Shpiro N; Márquez R; Cuenda A
J Biol Chem; 2005 May; 280(20):19472-9. PubMed ID: 15755732
[TBL] [Abstract][Full Text] [Related]
6. Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase.
Sullivan JE; Holdgate GA; Campbell D; Timms D; Gerhardt S; Breed J; Breeze AL; Bermingham A; Pauptit RA; Norman RA; Embrey KJ; Read J; VanScyoc WS; Ward WH
Biochemistry; 2005 Dec; 44(50):16475-90. PubMed ID: 16342939
[TBL] [Abstract][Full Text] [Related]
7. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
Namboodiri HV; Bukhtiyarova M; Ramcharan J; Karpusas M; Lee Y; Springman EB
Biochemistry; 2010 May; 49(17):3611-8. PubMed ID: 20337484
[TBL] [Abstract][Full Text] [Related]
8. The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38alpha for high throughput screening binding assay.
Tecle H; Feru F; Liu H; Kuhn C; Rennie G; Morris M; Shao J; Cheng AC; Gikunju D; Miret J; Coli R; Xi SH; Clugston SL; Low S; Kazmirski S; Ding YH; Cao Q; Johnson TL; Deshmukh GD; DiNitto JP; Wu JC; English JM
Chem Biol Drug Des; 2009 Dec; 74(6):547-59. PubMed ID: 19843080
[TBL] [Abstract][Full Text] [Related]
9. Structural basis and biological consequences for JNK2/3 isoform selective aminopyrazoles.
Park H; Iqbal S; Hernandez P; Mora R; Zheng K; Feng Y; LoGrasso P
Sci Rep; 2015 Jan; 5():8047. PubMed ID: 25623238
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796).
Regan J; Capolino A; Cirillo PF; Gilmore T; Graham AG; Hickey E; Kroe RR; Madwed J; Moriak M; Nelson R; Pargellis CA; Swinamer A; Torcellini C; Tsang M; Moss N
J Med Chem; 2003 Oct; 46(22):4676-86. PubMed ID: 14561087
[TBL] [Abstract][Full Text] [Related]
11. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
Suplatov D; Kopylov K; Sharapova Y; Švedas V
J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
[TBL] [Abstract][Full Text] [Related]
12. Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes.
Angell RM; Angell TD; Bamborough P; Bamford MJ; Chung CW; Cockerill SG; Flack SS; Jones KL; Laine DI; Longstaff T; Ludbrook S; Pearson R; Smith KJ; Smee PA; Somers DO; Walker AL
Bioorg Med Chem Lett; 2008 Aug; 18(15):4433-7. PubMed ID: 18602262
[TBL] [Abstract][Full Text] [Related]
13. The structure of phosphorylated p38gamma is monomeric and reveals a conserved activation-loop conformation.
Bellon S; Fitzgibbon MJ; Fox T; Hsiao HM; Wilson KP
Structure; 1999 Sep; 7(9):1057-65. PubMed ID: 10508788
[TBL] [Abstract][Full Text] [Related]
14. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells.
He D; Zhao XQ; Chen XG; Fang Y; Singh S; Talele TT; Qiu HJ; Liang YJ; Wang XK; Zhang GQ; Chen ZS; Fu LW
PLoS One; 2013; 8(1):e54181. PubMed ID: 23349819
[TBL] [Abstract][Full Text] [Related]
15. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
16. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
Dietrich J; Hulme C; Hurley LH
Bioorg Med Chem; 2010 Aug; 18(15):5738-48. PubMed ID: 20621496
[TBL] [Abstract][Full Text] [Related]
17. p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage.
Park JK; Fischer R; Dechend R; Shagdarsuren E; Gapeljuk A; Wellner M; Meiners S; Gratze P; Al-Saadi N; Feldt S; Fiebeler A; Madwed JB; Schirdewan A; Haller H; Luft FC; Muller DN
Hypertension; 2007 Mar; 49(3):481-9. PubMed ID: 17224470
[TBL] [Abstract][Full Text] [Related]
18. Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.
Xing L; Shieh HS; Selness SR; Devraj RV; Walker JK; Devadas B; Hope HR; Compton RP; Schindler JF; Hirsch JL; Benson AG; Kurumbail RG; Stegeman RA; Williams JM; Broadus RM; Walden Z; Monahan JB
Biochemistry; 2009 Jul; 48(27):6402-11. PubMed ID: 19496616
[TBL] [Abstract][Full Text] [Related]
19. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
Frembgen-Kesner T; Elcock AH
J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds.
Murali Dhar TG; Wrobleski ST; Lin S; Furch JA; Nirschl DS; Fan Y; Todderud G; Pitt S; Doweyko AM; Sack JS; Mathur A; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2007 Sep; 17(18):5019-24. PubMed ID: 17664068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
